Lilly’s revenue soars 48%, driven by demand for its GLP-1s
Lilly’s sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.
Lilly’s sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss. This story matters for Finance & Markets readers tracking fund. Reported by marketwatch.com. Read the full original at the source link below.
Originally reported by marketwatch.com. FundNews curates and briefs the finance & markets stories that matter. Our editorial policy →